glp 1 agonist alcohol use disorder GLP-1 Receptor Agonists and Research to Treat Overeating and Substance Disorders GLP-1 Weight Loss and Alcohol:

For instance, the subcutaneously injected drug Semaglutide 2.4 mg, approved in 2021 and administered once a week, has been shown to achieve an average weight reduction of 15%-17% and also offers cardiovascular protective effects

At the same time, a growing number of people are being prescribed semaglutide medications such as Ozempic , Wegovy , and Rybelsus for blood sugar control or weight management

International Agency for Research on Cancer Handbook Working Group

Despite their exploding popularity, the current GLP-1 injections (semaglutide though is also orally available) face accessibility issues due to cost and adverse effects and thus the next big move for the space, an easy to - pop pill could be lucrative, for which clinical trials are already well underway